Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma

Table 2 Clinical outcome details for 16 patients surviving ≥ 23 months including survival times (to follow-up at end 2010 or death) in months, disease sites at commencement of vaccination, treatments prior to commencement of vaccination and current status

Survival (Months)	ID	Disease sites	Prior Tx	Status
121	015	s/c, LN	S, R	Alive, fully functional
117	002	S/C, lung, LN	S, B	Alive, fully functional
93	010	s/c	S, ILI	Alive, fully functional
76	021	s/c	S, ILI	Alive, fully functional
61	031	s/c, lung, LN	S, R	Alive, fully functional
44	008	s/c	S	Died
35	049	s/c, lung	S	AWD, fully functional
34	050	s/c, LN, brain, spleen	R, S	Alive, fully functional
34	046	s/c, lung	S	Died
33	053	s/c, lung	S	Alive, fully functional
29	023	S/C, GB, lung	S	Died
27	052	s/c, umbilical	S	Off trial/died
26	045	s/c	S	Died
24	006	s/c	S	Died
24	017	s/c, LN, lung, liver, spleen	S	Died
23	009	S/C, Bone, lung	S, R	Died

Abbreviations: s/csub-cutaneous, LN lymph nodes, GB gall bladder, S surgery, B biological therapy, ILI isolated limb infusion (of chemotherapy), R radiotherapy, AWD alive with disease.